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Abstract: The history of biomarkers and ultrasonography dates back over more than 50 years.
The present status of biomarkers used in the context of ovarian cancer is addressed. Attention
is given to new interpretations of the etiology of ovarian cancer. Cancer antigen 125 (CA125) and
multivariate index assays (Ova1, Risk of Ovarian Malignancy Algorithm, Overa) are biomarker-driven
considerations that are presented. Integration of biomarkers into ovarian cancer diagnostics and
screening are presented in conjunction with ultrasound. Consideration is given to the serial
application of both biomarkers and ultrasound, as well as morphology-based indices. Attempts
are made to foresee how individualized molecular signatures may be able to both provide an alert
of the potential for ovarian cancer and to provide molecular treatments tailored to a personalized
genetic signature. In the future, an annual pelvic ultrasound and a comprehensive serum biomarker
screening/diagnostic panel may replace the much maligned bimanual examination as part of the
annual gynecologic examination. Taken together, it is likely that a new medical specialty for
screening and early diagnostics will emerge for physicians and epidemiologists, a field of study that
is independent of patient gender, organ, or the subspecialties of today.
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As one year closes and another begins, I find myself reflecting on ovarian cancer diagnostics. It is
truly humbling how little we have accomplished in this field over the last half-century. All the while,
the rest of the world has been busy. Since the first biomarker was reported, we have harnessed the
atom and ushered in the Nuclear Age. Since the first ovarian biomarker was reported, we have invented
the integrated circuit and spawned the dynamic Information Age. Yet, as gynecologic oncologists, we
continue to struggle with the early identification of ovarian cancer and whether ovarian cancer actually
begins in the ovary at all. The first serum biomarker for epithelial ovarian cancer was introduced
in 1965 (carcinoembyonic antigen, CEA) [1]. This was a milestone in cancer diagnostics, as prior to
this, oncologists were equipped with little to detect or monitor ovarian cancer. Keep in mind that
this was when ultrasound was just emerging as a very rudimentary medical diagnostic instrument,
and well before the advent of computed tomography (CT) or magnetic resonance imaging (MRI).
Now some fifty years later, it is easy to ask, “Why haven’t we done more?” Perhaps the recent focus on
molecular-genetic technology and personalized cancer treatment will inspire a new Diagnostic Age in
oncology. I am an optimist at heart, and am hopeful that our biomarker story will read somewhat like
the Charles Dickens novella, A Christmas Carol, where the return of Jacob Marley’s ghost 7 years after
his death helps give clarity to the past, present, and yet-to-come.
First, it is important to clarify our diagnostic objective. My generation has believed, quite sensibly
I think, that epithelial ovarian cancer arises from the ovary. Ovarian cancer has always utilized
a taxonomy-based classification system first introduced in the 1930s, then validated by the World
Health Organization’s Classification in 1973, and propagated into modern day. The story was as
follows: ovarian epithelial inclusion cysts are trapped beneath the surface epithelium of the ovary
and eventually undergo malignant transformation giving rise to invasive cancer. It was all a little
mysterious and the association with ovulation was difficult to validate, but “incessant ovulation”
did appear to be a significant risk factor. Until recently, true fallopian tube cancers were very rare.
The historic requirement for the diagnosis of a fallopian tube cancer included the following: (1) the
main tumor is grossly in the fallopian tube; (2) microscopically, the mucosa is chiefly involved and has
a papillary pattern; and (3) if the tubal wall is involved to a great extent, the transition between benign
and malignant tubal epithelium should be demonstrated [2]. Truthfully, many serous “ovarian cancers”
probably do begin elsewhere and metastasize to the ovary since ovarian stromal involvement is the
principle requirement to categorize a malignancy as primary ovarian cancer. Since serous peritoneal,
fallopian tube, and ovarian cancers are histologically and morphologically similar regardless of where
they begin, and are treated alike, they have been collectively categorized as ovarian cancer. Today,
our approach to treatment is based on this premise, specifically that all these cancers are lumped
together as one. National collaborative group trials for ovarian cancer have typically studied all three
malignancies together rather than individually, even non-serous cell types. And this was very sensible,
since we thought of ovarian cancer in terms of its anatomic origin and combining made practical sense
for clinical trial accrual. This dilemma is apropos given the current belief that the fallopian tube (serous
tubal intraepithelial carcinoma, STIC) may be the primary culprit in the etiology of many serous
cancers of the ovary [3]. It is very helpful to know what the target is, not just for purposes of tidiness
and taxonomy, but also for understanding how to envision the next generation of diagnostic tests.
Kurman and coauthors recently described the need for a paradigm shift in our understanding of
ovarian cancer [4]. Endometrial precursors are likely responsible for many of the Type I ovarian cancers
as endometrioid and clear cell types originate ostensibly from endometriotic implants. These are
typically indolent, low-grade malignancies, and endometrioid, transitional and clear cell cancers
with distinct molecular markers: KRAS, BRAF, ERB-2, PTEN and others, but not TP-53. And most
gastrointestinal-type tumors involving the ovary are also secondary malignancies, with primary
mucinous ovarian cancers comprising only 3% of all epithelial ovarian cancers. Fallopian tube
precursors are likely the cause of the more common Type II, high-grade serous ovarian cancers which
are characterized by TP-53 mutations. In the end, stromal and germ cell tumors may be the only
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true anatomic ovarian malignancies. The challenge of course, is that all gynecologic cancers are not
organ-specific, so our diagnostic and treatment strategies need to evolve.
1. Past
The biomarker past was an era of single-marker diagnostics. CEA was first described in 1965 as
a serum biomarker for mucinous colon cancer, and in 1976 as a blood test for women with ovarian
cancer [1,5]. At the time, this was a tremendous advance in science. Not long after, cancer antigen 125
(CA125) was announced as a serum biomarker specific for ovarian cancer [6] (Table 1). To move from
an age of very limited imaging and diagnostics to an ovarian cancer blood test was transformational.
In retrospect, it can be argued that CA125 has done little to improve ovarian cancer care. The Food and
Drug Administration (FDA) never approved CA125 for preoperative use in the United States, but only
for cancer surveillance for women with a known diagnosis of ovarian cancer. Ironically, the majority
of CA125 tests ordered today are for the evaluation of an ovarian tumor prior to surgery. The use of
serum CA125 has also never been associated with a survival benefit, whether utilized before or after
diagnosis. This may be an indictment of the test itself, of the disease, the stage at diagnosis, treatment
options, or a combination of these factors.
Table 1. Common serum biomarkers for ovarian cancer, year of publication or Food and Drug
Administration (FDA) clearance. CEA, carcinoembyonic antigen; CA125, cancer antigen 125; ROMA,
Risk of Ovarian Malignancy Algorithm; HE4, human epididymis protein 4; Ova1 and Overa are








Although CA125 is the best-known serum ovarian cancer biomarker, it is not the only one: CEA
(mucinous), LDH (dysgerminoma, mixed germ cell tumors), β-hCG (choriocarcinoma, mixed germ
cell tumors), inhibin B (granulosa cell tumors), α-fetoprotein (yolk sac tumors, embryonal cell tumors),
and HE4 are also available. In 2008, HE4 was cleared by the FDA for use in monitoring patients with
a known diagnosis of ovarian cancer, able to detect recurrence of epithelial cancers 2 to 3 months in
advance of CA125. Like CA125, it does not have a preoperative diagnostic indication from the FDA.
CA125 is the most studied biomarker for serous epithelial cancer arising from the ovary, fallopian tube,
or peritoneal cavity, but it is neither a sensitive nor particularly specific cancer marker. This may partly
explain why its use has not translated into an improvement in patient survival. For 35 years, we have
been trying to overcome this biomarker’s inadequacy by combining it with other markers, combining
it with imaging, or monitoring its behavior over time: all ultimately without epic success. Success, our
patients have discovered, is identifying ovarian cancer in the earliest of stages where treatment can
have a lasting impact on survival. Our understanding of protein biomarkers has improved recently as
a result of advances in proteomic diagnostic technologies.
2. Present
In 2009, the FDA cleared the first preoperative serum biomarker test for ovarian cancer. After five
years of diagnostic discovery and systematic clinical testing, a 5-protein biomarker panel named
Ova1® became the first multivariate index assay (MIA) to gain clearance in the United States [7,8].
Ova1 combines the second generation CA125-II with other inflammatory and transport proteins
(transferrin, β-2 microglobulin, apolipoprotein A-1, and transthyretin) into a test result of low or high
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risk for ovarian cancer. The following year, a two-protein test was FDA-cleared that combined CA125
and HE4 (Risk of Ovarian Malignancy Algorithm, ROMA®) for identical indications [9]. These MIA
tests were a significant improvement for preoperative testing compared to single biomarker tests
because of increased sensitivity (Table 2) [10]. Importantly, these tests are not true diagnostic tests,
but rather triage or referral tests. When a woman is known to have an ovarian tumor that requires
surgery, these tests are used to determine the likelihood of malignancy. A primary care provider can
utilize the test to determine whether referral to a gynecologic oncologist is indicated. These tests have
two critical requirements: (1) a mass has been confirmed on imaging, and (2) the ovarian tumor has
already been determined to require surgery. Since the test itself is not used to determine whether
or not surgery is necessary, it should result in minimal tangible harm. Nationwide, the majority of
ovarian cancer surgeries are not initially performed by a gynecologic oncologist, so the hope is that the
quality of patient care and cancer survival will improve over time as appropriate referrals are made.
Provided that the two critical requirements are observed, this carefully considered strategy should
prevent unnecessary surgery from a falsely positive biomarker test, an important consideration for the
women, their doctors, and the FDA.
Table 2. Test performance for detecting ovarian cancer of all histologic types.
Biomarker Sensitivity Specificity
CA125 *,+,# 76% 94%
Ova1 * 94% 54%
ROMA ˆ 89% 83%
Overa * 91% 69%
* Studied in same patient population; + CA125-II assay (second generation); # CA125 not FDA-approved for
preoperative use; ˆ Meta-analysis [11]
Multivariate index assays have continued to evolve. In 2016, the FDA cleared a new generation
Ova1 test (Overa®) that essentially combines two MIA tests and maintains a high diagnostic sensitivity
with improved specificity [12], Table 2. The individual markers are CA125-II, HE4, apolipoprotein A-1,
follicle stimulating hormone, and transferrin. The preoperative indications are the same. Other panels
will soon follow [13]. Naturally, there are always temptations to move a diagnostic test into a
screening role, but without proper study, this is a premature and potentially harmful notion. Cancer
screening and cancer diagnostics are vastly different challenges with regard to disease prevalence and
endpoint objectives.
Ovarian biomarkers are not restricted to the blood. Ultrasound, like all imaging, is a biomarker
of disease. Ultrasound has been widely studied in the United States and Europe as a screening tool
and as a diagnostic adjunct. We are beginning to discover that ovarian ultrasound screening alone, or
in combination with CA125, may have the potential to save lives [14,15]. Findings from the United
Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) recently reported preliminary
results of a shift to early stage disease and a reduction in cancer deaths on follow up to 14 years with
multimodal ovarian cancer screening with serum CA125 interpreted using the Risk of Ovarian Cancer
Algorithm (ROCA), transvaginal ultrasound, and clinical assessment. ROCA is an algorithm used to
interpret longitudinal CA125 values for ovarian cancer screening. This story is far from over, but it is
definitely premature to begin screening the general population off protocol. In fact, shortly following
the UKCTOCS publication, the FDA, the American College of Obstetrics and Gynecology, and the
Society of Gynecologic Oncology all made prompt safety statements announcing that ROCA is not an
approved screening strategy and may trigger unnecessary surgical procedures.
How we combine biomarkers has a significant impact on their overall test performance. Tests can
be combined in series or parallel. When combined in series (A, B and C, etc.), the statistical consequence
is improved specificity at the expense of sensitivity. Conversely, tests combined in parallel (A or
B or C, etc.) will result in improved sensitivity with a compromise in specificity. At the risk of
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oversimplification, the MIA tests are essentially combining individual biomarker tests in a parallel
manner. Ova1 is a good example. Five biomarkers are applied in parallel in the same serum specimen
with resultant high sensitivity (and high negative predictive value), making it an excellent triage test.
If the test is low-risk, it is very unlikely to be malignant and the patient can have surgery without
consulting a specialist. But the apparent drawback of this MIA strategy can be a modest specificity
and ovarian tumors may have a high-risk test result even though cancer is not present. By requiring
that a mass be confirmed on imaging prior to ordering Ova1, there is a mandate of sorts to combine
an additional test (imaging) that localizes the problem to the ovary, improving both the sensitivity of
finding an abnormality and the specificity that the problem arises from the ovary (though not that it is
necessarily malignant).
Today, serum biomarkers alone are not enough. In developed countries, there is no practical
way to divorce serum biomarkers from ovarian imaging since ultrasound and CT scan are ubiquitous
tests available to nearly every woman. Ultrasound is far less expensive than a CT scan or MRI,
but ultrasound findings are limited mainly to the pelvis. An ultrasound-based morphology scoring
system is an effective and objective way to identify ovarian tumors at high-risk for malignancy.
The International Ovarian Tumor Analysis group (IOTA) has a multifaceted algorithm that has
been systematically evaluated in Europe to high acclaim [16]. There have also been attempts
to simplify the IOTA algorithm [17,18], and IOTA has yet to be evaluated in the United States.
Other morphology-based indices have been proposed and validated in the U.S. and abroad [19–21].
Moreover, much like longitudinal CA125 (ROCA), serial ultrasound offers improved diagnostic results
over a single evaluation (Figure 1) [22,23]. Serial ultrasonography is a sensible approach because each
tumor is evaluated both on its changing complexity and its physiologic evolution. There can be clinical
reasons not to perform serial evaluations on women with ovarian tumors. First, the presentation may
be so concerning for malignancy that prompt surgery is best. Second, the woman may be symptomatic
from the tumor so delayed intervention is problematic. Third, the patient may be traveling a great
distance or have other personal reasons why a delay in treatment is not feasible. In the absence of
these issues, a thoughtful re-evaluation is a valuable diagnostic option, and the data support this
concept for serum CA125 in ovarian cancer screening (ROCA) and serial ultrasound with a quantifiable
morphology index score in ovarian diagnostics (and maybe screening). The coup de gras, given our
present diagnostic capability, would be a combination of serial MIA biomarkers with serial ultrasound.
This data has yet to be published.
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3. Yet-To-Come
Dickens was artful in his portrayal of Ebenezer Scrooge, allowing him to see his unflattering
future through Marley’s ghost of Christmas yet-to-come. Of course, after his apparitional vision
on Christmas Eve, Scrooge awoke transformed. And transformation is what we need for ovarian
cancer diagnostics. It is certainly possible that new innovations will give rise to novel diagnostic
insights, just as cancer therapy is trending toward targeted, molecular-based treatment. Although
personalized cancer treatment is still far from the standard of care, it does raise the question, “Can we
pursue a similar evolution in ovarian cancer diagnostics?” After 50 years, it is regrettable that we are
still searching for effective approaches to early cancer diagnosis, but we are. As we transition our
thinking and our oncology research to a molecular genetic model, we will recognize that this will unite
malignancies in a different way, based on common molecular footprints rather than on an anatomic
location or a given oncology specialty.
In the near term, we will see new types of serum cancer biomarkers that outperform our current
protein-based markers in both selectivity and accuracy. Nucleic acids are showing promise as a
new group of serum markers, including free DNA, mRNA, microRNAs, and circulating tumor
DNA (ctDNA) [24,25]. A thoughtful combination of protein and nucleic acid markers may permit a
comprehensive screening and diagnostic panel that captures all gynecologic malignancies in one
blood test. In the future, an annual pelvic ultrasound and a comprehensive serum biomarker
screening/diagnostic panel may replace the much maligned bimanual examination as part of the
annual gynecologic examination. If abnormal, repeat testing will provide a personalized, serial database
that will recalculate the likelihood of malignancy based on the objective change over time in tumor
morphology and physiology. As the diagnosis and treatment of cancer changes, so too must clinical trial
design to accommodate the new era of multiple biomarkers and targeted, personalized therapies [26].
Beyond the near future, germ-line cancer testing will be initiated at birth as part of newborn
screening. Today, we often recommend genetic cancer testing following a malignant diagnosis, which
is helpful for their future screening and for their relatives, but it is obviously a little late to prevent their
own cancer. The power of knowing individual genetic risk at birth is that it may potentially modify
behavior in those found to have a germ-line mutation, which comprise 5%–10% of cancers, and permit
selective screening algorithms that are customized to personal cancer risk. And periodic genomic
screening throughout one’s lifetime may help identify acquired mutations that predispose to specific
cancers, heighten awareness, alter personal behavior, and dictate medical surveillance. The technology
to sort, store and personalize this colossal amount of data is available today, a consequence of Moore’s
law whereby computer processing speeds and power have roughly doubled every two years beginning
in the 1960s. Cancer testing will quickly move beyond organ and specialty-specific screening. Whole
body scans and universal cancer panels will screen and monitor all cancers, solid and hematogenous.
An asymptomatic patient may not even need to see a physician if the annual evaluation is normal.
A new medical field for screening and early diagnostics will emerge for physicians and epidemiologists,
a field of study that is independent of patient gender, organ, or the subspecialties of today.
To get there, we must agree to work with industry innovators in medicine, technology and finance
to develop and fund novel strategies for diagnosis and screening. We must encourage the national
collaborative groups and the National Cancer Institute’s Clinical Trials Reporting Program to promote
screening and diagnostic trials with as much vigor as the interventional treatment trials. Since the
early detection of any cancer has the promise of shifting diagnosis to an earlier stage, cancer survival
will improve. This approach could ultimately revolutionize how we provide care for our patients, and
perhaps spare us yet another salvage chemotherapy trial for relapsed ovarian cancer.
So let us awake on a future Christmas morning with newfound clarity. Let us transform how we
categorize ovarian cancer, how we identify ovarian cancer, how we treat ovarian cancer, and possibly
how we screen for cancer in general. It did not take long for the Nuclear Age to change our worldview or
for the Information Age to profoundly alter our daily lives; with any luck, it will not take long to revisit
our approach to early diagnostics for ovarian cancer. If Ebenezer Scrooge can change his ways . . .
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